Ta strona została przetłumaczona automatycznie i dokładność tłumaczenia nie jest gwarantowana. Proszę odnieść się do angielska wersja za tekst źródłowy.

Personalizowana Repetytywna Przezczaszkowa Stymulacja Magnetyczna (PrTMS) w Leczeniu Zaburzenia Stresu Pourazowego (PTSD)

10 listopada 2026 zaktualizowane przez: Kaloyan Tanev, MD, Massachusetts General Hospital

Spersonalizowana Powtarzalna Przezczaszkowa Stymulacja Magnetyczna (PrTMS) w Leczeniu Zespołu Stresu Pourazowego (PTSD)

This study is testing a personalized form of brain stimulation called PrTMS as a treatment for post-traumatic stress disorder (PTSD) in military service members and veterans. Unlike standard approaches, this treatment uses a simple brainwave test (EEG) to tailor the therapy to each individual. Participants will be randomly assigned to receive either active treatment or a comparison (sham) treatment over 6 weeks. Researchers will track changes in PTSD symptoms, mood, sleep, and overall well-being, including using wearable devices to measure things like sleep and heart rate. The goal is to see whether this personalized approach can provide greater and longer-lasting relief for individuals living with PTSD.

Przegląd badań

Status

Jeszcze nie rekrutacja

Warunki

Interwencja / Leczenie

Szczegółowy opis

This study is a randomized, double-blind, sham-controlled trial evaluating a personalized approach to repetitive transcranial magnetic stimulation (PrTMS) for the treatment of post-traumatic stress disorder (PTSD) in military service members and veterans. PrTMS integrates spectral electroencephalography (sEEG) with neurocognitive assessments to individualize stimulation parameters, including frequency and intensity, and to allow for dynamic adjustment over the course of treatment based on each participant's evolving neurophysiological profile. Participants will undergo a 6-week treatment protocol (5 sessions per week), followed by longitudinal assessments over 6 months to evaluate durability of response. Multimodal outcomes will include clinician-administered and self-report measures of PTSD, mood, anxiety, and sleep, as well as physiologic and behavioral data collected via wearable devices. This study is designed to determine whether EEG-guided, precision neuromodulation improves clinical outcomes compared to standard, non-personalized stimulation approaches and to inform the development of individualized treatment strategies in PTSD.

Typ studiów

Interwencyjne

Zapisy (Szacowany)

100

Faza

  • Nie dotyczy

Kontakty i lokalizacje

Ta sekcja zawiera dane kontaktowe osób prowadzących badanie oraz informacje o tym, gdzie badanie jest przeprowadzane.

Kontakt w sprawie studiów

Kopia zapasowa kontaktu do badania

Lokalizacje studiów

    • Massachusetts
      • Charlestown, Massachusetts, Stany Zjednoczone, 02129
        • Home Base
        • Kontakt:
        • Główny śledczy:
          • Sofia E Matta, MD

Kryteria uczestnictwa

Badacze szukają osób, które pasują do określonego opisu, zwanego kryteriami kwalifikacyjnymi. Niektóre przykłady tych kryteriów to ogólny stan zdrowia danej osoby lub wcześniejsze leczenie.

Kryteria kwalifikacji

Wiek uprawniający do nauki

18 lat i starsze (Dorosły, Starszy dorosły)

Akceptuje zdrowych ochotników

Nie

Płeć kwalifikująca się do nauki

Wszystko

Opis

Inclusion Criteria:

  • Reserve or former member of the military (veteran status)
  • Age 18 years or older
  • Primary diagnosis of post-traumatic stress disorder (PTSD) confirmed by the - Clinician-Administered PTSD Scale for DSM-5 (CAPS-5)
  • Post-Traumatic Stress Disorder Checklist for DSM-5 (PCL-5) score ≥ 33, indicating clinically significant PTSD symptoms
  • Proficient in English (spoken and written) to ensure understanding of study procedures and informed consent

Exclusion Criteria:

  • History of open-skull traumatic brain injury
  • Clinically significant seizure disorder or history of manic episodes
  • Neurological conditions associated with increased risk (e.g., increased intracranial pressure, brain lesions, stroke, cerebral aneurysm)
  • Electroencephalogram (EEG) abnormalities suggesting elevated seizure risk
  • Repetitive transcranial magnetic stimulation (rTMS) within 3 months prior to screening
  • Current use of antipsychotic or anticonvulsant medications
  • Presence of intracranial implants or non-removable metal in or near the head (excluding the mouth)
  • Clinically significant or unstable medical conditions, including active suicidal ideation
  • Uncontrolled medical illness (e.g., thyroid, hepatic, cardiac, pulmonary, or renal disease)
  • Initiation of PTSD-specific treatment within the past 4 weeks (participants on a stable regimen may be eligible)
  • Pregnancy (for women of childbearing potential)
  • Any condition that, in the opinion of the investigator, may interfere with study participation or completion

Plan studiów

Ta sekcja zawiera szczegółowe informacje na temat planu badania, w tym sposób zaprojektowania badania i jego pomiary.

Jak projektuje się badanie?

Szczegóły projektu

  • Główny cel: Leczenie
  • Przydział: Randomizowane
  • Model interwencyjny: Przydział równoległy
  • Maskowanie: Podwójnie

Broń i interwencje

Grupa uczestników / Arm
Interwencja / Leczenie
Aktywny komparator: Active PrTMS (EEG-Guided rTMS)

Participants receive personalized, EEG-guided repetitive transcranial magnetic stimulation (PrTMS) administered 5 days per week for 6 weeks, with stimulation parameters individualized and adjusted over time based on serial sEEG and neurocognitive assessments.

Personalized repetitive transcranial magnetic stimulation (PrTMS) is delivered using the Neurocare Apollo TMS Therapy System for 30 minutes per session, 5 days per week, over 6 weeks. Stimulation parameters (frequency 8-13 Hz and intensity typically 50-60% of motor threshold) are individualized based on baseline and serial spectral EEG (sEEG) assessments, with adjustments made throughout treatment to optimize response.

Pozorny komparator: Sham PrTMS

Participants receive sham repetitive transcranial magnetic stimulation (rTMS) administered 5 days per week for 6 weeks using a sham coil that mimics the sound and sensation of active treatment without delivering a therapeutic magnetic field.

Sham stimulation will be delivered using the same Neurocare Apollo TMS Therapy System as the active intervention, with identical treatment schedule (5 days per week for 6 weeks; 30 minutes per session). A sham coil identical in appearance to the active coil will be used, which does not generate a therapeutic magnetic field. To mimic the sensory experience of active treatment, the sham procedure will produce similar auditory clicking and will include a surface electrical stimulation (TENS) applied to the forehead to replicate scalp sensations and mild muscle contraction. This approach is designed to maintain blinding while delivering no active neuromodulatory effect.

Co mierzy badanie?

Podstawowe miary wyniku

Miara wyniku
Opis środka
Ramy czasowe
Clinician-Administered PTSD Scale for DSM-5 (CAPS-5)
Ramy czasowe: At baseline and the end of treatment at Week 6.

The Clinician-Administered PTSD Scale for DSM-5 (CAPS-5) is a structured interview and gold standard for diagnosing and assessing PTSD in clinical and research settings. It assesses current or lifetime PTSD based on DSM-5 criteria and measures symptom severity across the 20 PTSD symptoms, including the dissociative subtype, in relation to a single index traumatic event. Total severity scores range from 0 to 80, with higher scores indicating worse PTSD symptom severity.

At baseline and the end of treatment at Week 6.

Miary wyników drugorzędnych

Miara wyniku
Opis środka
Ramy czasowe
Post-Traumatic Stress Disorder Checklist for DSM-5 (PCL-5)
Ramy czasowe: At baseline, and weekly during Weeks 1-6, and at Week 10, Week 22, and Week 34.

The Post-Traumatic Stress Disorder Checklist for DSM-5 (PCL-5) is a 20-item self-report measure that assesses PTSD symptom presence and severity across DSM-5 symptom clusters, including re-experiencing, avoidance, negative alterations in cognition and mood, and arousal. Total scores range from 0 to 80, with higher scores indicating greater PTSD symptom severity.

At baseline, and weekly during Weeks 1-6, and at Week 10, Week 22, and Week 34.
Generalized Anxiety Disorder-7 (GAD-7)
Ramy czasowe: At baseline, and weekly during Weeks 1-6, and at Week 10, Week 22, and Week 34.

The Generalized Anxiety Disorder-7 (GAD-7) is a seven-item self-report scale used to assess the severity of generalized anxiety symptoms and to screen for anxiety over the past two weeks. Total scores range from 0 to 21, with higher scores indicating greater anxiety severity.

At baseline, and weekly during Weeks 1-6, and at Week 10, Week 22, and Week 34.
Patient Health Questionnaire-9 (PHQ-9)
Ramy czasowe: At baseline, and weekly during Weeks 1-6, and at Week 10, Week 22, and Week 34.

The Patient Health Questionnaire-9 (PHQ-9) is a 9-item self-report measure used to screen, diagnose, monitor, and assess the severity of depression. Total scores range from 0 to 27, with higher scores indicating greater depression severity.

At baseline, and weekly during Weeks 1-6, and at Week 10, Week 22, and Week 34.
Tinnitus Functional Index (TFI)
Ramy czasowe: At baseline, and weekly during Weeks 1-6, and at Week 10, Week 22, and Week 34.

The Tinnitus Functional Index (TFI) is a 25-item self-report questionnaire designed to measure the severity, negative impact, and treatment-related changes of tinnitus on a person's daily life over the past week. Total scores range from 0 to 100, with higher scores indicating greater tinnitus severity and functional impact.

At baseline, and weekly during Weeks 1-6, and at Week 10, Week 22, and Week 34.
TMS Tolerability Worksheet (TTW)
Ramy czasowe: At baseline and weekly during Weeks 1-6.

The TMS Tolerability Worksheet (TTW) is a clinician-administered tool used to document session-related side effects and adverse events associated with transcranial magnetic stimulation (TMS), including symptoms such as headache, neck pain, discomfort at the stimulation site, and hearing changes, with severity categorized as none, mild, moderate, or severe.

At baseline and weekly during Weeks 1-6.
Pittsburgh Sleep Quality Index Addendum (PSQI-A)
Ramy czasowe: At baseline, and weekly during Weeks 1-6, and at Week 10, Week 22, and Week 34.

The Pittsburgh Sleep Quality Index Addendum for PTSD (PSQI-A) is a self-report measure that assesses disruptive nocturnal behaviors associated with PTSD, including nightmares, panic, hot flashes, and acting out dreams. Total scores range from 0 to 21, with higher scores indicating greater severity of disruptive nocturnal behaviors.

At baseline, and weekly during Weeks 1-6, and at Week 10, Week 22, and Week 34.
Total Sleep Time (Oura Ring)
Ramy czasowe: Continuously from enrollment through Week 6, and at follow-up at Week 10, Week 22, and Week 34.

Total sleep time, measured in hours per night using the Oura Ring wearable device.

Continuously from enrollment through Week 6, and at follow-up at Week 10, Week 22, and Week 34.
Sleep Efficiency (Oura Ring)
Ramy czasowe: Continuously from enrollment through Week 6, and at follow-up at Week 10, Week 22, and Week 34.

Sleep efficiency, expressed as a percentage (0-100%) representing the ratio of time spent asleep relative to the total time in bed, using the Oura Ring wearable device.

Continuously from enrollment through Week 6, and at follow-up at Week 10, Week 22, and Week 34.
Sleep Latency (Oura Ring)
Ramy czasowe: Continuously from enrollment through Week 6, and at follow-up at Week 10, Week 22, and Week 34.

Sleep latency, measured in minutes, defined as the time from the start of the sleep period to sleep onset, as recorded by the Oura Ring wearable device. Typical values range from approximately 0 to 60 minutes.

Continuously from enrollment through Week 6, and at follow-up at Week 10, Week 22, and Week 34.
REM Sleep Duration (Oura Ring)
Ramy czasowe: Continuously from enrollment through Week 6, and at follow-up at Week 10, Week 22, and Week 34.

Duration of rapid eye movement (REM) sleep, measured in minutes using the Oura Ring wearable device.

Continuously from enrollment through Week 6, and at follow-up at Week 10, Week 22, and Week 34.
REM Sleep Percentage (Oura Ring)
Ramy czasowe: Continuously from enrollment through Week 6, and at follow-up at Week 10, Week 22, and Week 34.

REM sleep expressed as a percentage of total sleep time, measured using the Oura Ring wearable device.

Continuously from enrollment through Week 6, and at follow-up at Week 10, Week 22, and Week 34.
Light Sleep Duration (Oura Ring)
Ramy czasowe: Continuously from enrollment through Week 6, and at follow-up at Week 10, Week 22, and Week 34.

Duration of light sleep, measured in minutes using the Oura Ring wearable device.

Continuously from enrollment through Week 6, and at follow-up at Week 10, Week 22, and Week 34.
Light Sleep Percentage (Oura Ring)
Ramy czasowe: Continuously from enrollment through Week 6, and at follow-up at Week 10, Week 22, and Week 34.

Light sleep expressed as a percentage of total sleep time, measured using the Oura Ring wearable device.

Continuously from enrollment through Week 6, and at follow-up at Week 10, Week 22, and Week 34.
Deep Sleep Duration (Oura Ring)
Ramy czasowe: Continuously from enrollment through Week 6, and at follow-up at Week 10, Week 22, and Week 34.

Duration of deep (slow-wave) sleep, measured in minutes using the Oura Ring wearable device.

Continuously from enrollment through Week 6, and at follow-up at Week 10, Week 22, and Week 34.
Deep Sleep Percentage (Oura Ring)
Ramy czasowe: Continuously from enrollment through Week 6, and at follow-up at Week 10, Week 22, and Week 34.

Deep (slow-wave) sleep expressed as a percentage of total sleep time, measured using the Oura Ring wearable device.

Continuously from enrollment through Week 6, and at follow-up at Week 10, Week 22, and Week 34.
Resting Heart Rate (Oura Ring)
Ramy czasowe: Continuously from enrollment through Week 6, and at follow-up at Week 10, Week 22, and Week 34.

Resting heart rate, measured in beats per minute (bpm) using the Oura Ring wearable device.

Continuously from enrollment through Week 6, and at follow-up at Week 10, Week 22, and Week 34.
Heart Rate Variability (Oura Ring)
Ramy czasowe: Continuously from enrollment through Week 6, and at follow-up at Week 10, Week 22, and Week 34.

Heart rate variability (HRV), measured in milliseconds (ms) using the Oura Ring wearable device.

Continuously from enrollment through Week 6, and at follow-up at Week 10, Week 22, and Week 34.
Body Temperature (Oura Ring)
Ramy czasowe: Continuously from enrollment through Week 6, and at follow-up at Week 10, Week 22, and Week 34.

Nightly body temperature deviation from baseline, measured in degrees Fahrenheit (°F) using the Oura Ring wearable device.

Continuously from enrollment through Week 6, and at follow-up at Week 10, Week 22, and Week 34.
Daily Step Count (Oura Ring)
Ramy czasowe: Continuously from enrollment through Week 6, and at follow-up at Week 10, Week 22, and Week 34.

Daily step count, measured as the number of steps per day using the Oura Ring wearable device.

Continuously from enrollment through Week 6, and at follow-up at Week 10, Week 22, and Week 34.
Active Energy Expenditure (Oura Ring)
Ramy czasowe: Continuously from enrollment through Week 6, and at follow-up at Week 10, Week 22, and Week 34.

Active energy expenditure, measured in kilocalories per day (kcal/day) using the Oura Ring wearable device.

Continuously from enrollment through Week 6, and at follow-up at Week 10, Week 22, and Week 34.
Total Energy Expenditure (Oura Ring)
Ramy czasowe: Continuously from enrollment through Week 6, and at follow-up at Week 10, Week 22, and Week 34.

Total energy expenditure, measured in kilocalories per day (kcal/day) using the Oura Ring wearable device.

Continuously from enrollment through Week 6, and at follow-up at Week 10, Week 22, and Week 34.
Sedentary Activity Duration (Oura Ring)
Ramy czasowe: Continuously from enrollment through Week 6, and at follow-up at Week 10, Week 22, and Week 34.

Duration of sedentary activity, measured in minutes per day using the Oura Ring wearable device.

Continuously from enrollment through Week 6, and at follow-up at Week 10, Week 22, and Week 34.
Light Activity Duration (Oura Ring)
Ramy czasowe: Continuously from enrollment through Week 6, and at follow-up at Week 10, Week 22, and Week 34.

Duration of light physical activity, measured in minutes per day using the Oura Ring wearable device.

Continuously from enrollment through Week 6, and at follow-up at Week 10, Week 22, and Week 34.
Moderate Activity Duration (Oura Ring)
Ramy czasowe: Continuously from enrollment through Week 6, and at follow-up at Week 10, Week 22, and Week 34.

Duration of moderate physical activity, measured in minutes per day using the Oura Ring wearable device.

Continuously from enrollment through Week 6, and at follow-up at Week 10, Week 22, and Week 34.
Vigorous Activity Duration (Oura Ring)
Ramy czasowe: Continuously from enrollment through Week 6, and at follow-up at Week 10, Week 22, and Week 34.

Duration of vigorous physical activity, measured in minutes per day using the Oura Ring wearable device.

Continuously from enrollment through Week 6, and at follow-up at Week 10, Week 22, and Week 34.

Współpracownicy i badacze

Tutaj znajdziesz osoby i organizacje zaangażowane w to badanie.

Sponsor

Współpracownicy

Śledczy

  • Główny śledczy: Kaloyan S Tanev, MD, Massachusetts General Hospital

Publikacje i pomocne linki

Osoba odpowiedzialna za wprowadzenie informacji o badaniu dobrowolnie udostępnia te publikacje. Mogą one dotyczyć wszystkiego, co jest związane z badaniem.

Daty zapisu na studia

Daty te śledzą postęp w przesyłaniu rekordów badań i podsumowań wyników do ClinicalTrials.gov. Zapisy badań i zgłoszone wyniki są przeglądane przez National Library of Medicine (NLM), aby upewnić się, że spełniają określone standardy kontroli jakości, zanim zostaną opublikowane na publicznej stronie internetowej.

Główne daty studiów

Rozpoczęcie studiów (Szacowany)

1 czerwca 2027

Zakończenie podstawowe (Szacowany)

31 maja 2029

Ukończenie studiów (Szacowany)

31 grudnia 2029

Daty rejestracji na studia

Pierwszy przesłany

24 marca 2026

Pierwszy przesłany, który spełnia kryteria kontroli jakości

10 kwietnia 2026

Pierwszy wysłany (Rzeczywisty)

13 kwietnia 2026

Aktualizacje rekordów badań

Ostatnia wysłana aktualizacja (Rzeczywisty)

13 listopada 2026

Ostatnia przesłana aktualizacja, która spełniała kryteria kontroli jakości

10 listopada 2026

Ostatnia weryfikacja

1 listopada 2026

Więcej informacji

Terminy związane z tym badaniem

Inne numery identyfikacyjne badania

  • 2025P003206

Plan dla danych uczestnika indywidualnego (IPD)

Planujesz udostępniać dane poszczególnych uczestników (IPD)?

NIE

Opis planu IPD

Individual participant data (IPD) will not be shared. Only de-identified, aggregate data may be shared with collaborators, including the United States Air Force Research Laboratory (USAFRL), under a data sharing agreement.

Informacje o lekach i urządzeniach, dokumenty badawcze

Bada produkt leczniczy regulowany przez amerykańską FDA

Nie

Bada produkt urządzenia regulowany przez amerykańską FDA

Tak

produkt wyprodukowany i wyeksportowany z USA

Nie

Te informacje zostały pobrane bezpośrednio ze strony internetowej clinicaltrials.gov bez żadnych zmian. Jeśli chcesz zmienić, usunąć lub zaktualizować dane swojego badania, skontaktuj się z register@clinicaltrials.gov. Gdy tylko zmiana zostanie wprowadzona na stronie clinicaltrials.gov, zostanie ona automatycznie zaktualizowana również na naszej stronie internetowej .